MaaT Pharma: Phase 3 trial recruitment completed

(CercleFinance.com) - MaaT Pharma rose on Tuesday's trading on the Paris Bourse after announcing the completion of enrolment in its Phase 3 trial for the treatment of acute graft-versus-host disease.


The trial aims to evaluate its most advanced drug candidate, MaaT013, for the treatment of steroid-refractory acute graft-versus-host disease (aGvH) that is refractory or intolerant to ruxolitinib.

With the treatment of the last patient, initial results, starting with whether or not the primary endpoint has been met, are now expected from January 2025 onwards.

MaaT013 enables targeted modulation of the immune system, restoring the balance of the intestinal microbiota and minimizing the risks of adverse effects frequently associated with conventional immunosuppressive treatments in oncology.

From the Lyon-based biotech's point of view, this is one of the "most important steps in the company's development", which leads it to anticipate the initiation of a registration process with submission scheduled for 2025 in Europe.

On the Paris Bourse, MaaT Pharma shares advanced by 1.1% following these announcements, bringing to just 25% their gains over the past 12 months.

Copyright (c) 2024 CercleFinance.com. All rights reserved.